<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Vadivalagan C</submitter><funding>NCI NIH HHS</funding><funding>Division of Cancer Prevention, National Cancer Institute</funding><pagination>6079-6090</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12701774</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(12)</volume><pubmed_abstract>Hepatocellular carcinoma (HCC), commonly associated with cirrhosis, is a major cause of cancer-related mortality due to its poor prognosis. Herein, we investigated fucosylated glycoforms of serum haptoglobin (Hp) as potential biomarkers for HCC of metabolic associated dysfunction associated liver disease (MASLD) and alcohol related liver disease (ALD) etiologies. We analyzed 119 patient samples, including 60 with cirrhosis and 59 with HCC. Isolated Hp protein was digested using trypsin and Glu-C, and site-specific &lt;i>N&lt;/i>-glycans were quantified using PRM with LC-HCD-MS/MS. Differential analysis revealed significant variations in fucosylated tetra-antennary glycoforms at N241(VVLHPN&lt;sup>241&lt;/sup>YSQVD and VVLHPN&lt;sup>241&lt;/sup>YSQVDIGLIK), particularly in distinguishing cirrhosis and HCC (&lt;i>P&lt;/i> &lt; 0.05). A combined analysis of identified tetra-antennary fucosylated markers, along with AFP, gender, and age, demonstrated improved AUC. Tetra-antennary glycoforms exhibited an AUC of 0.871 (95% CI: 0.80-0.93) when incorporated into the AFP + age + gender + marker panel compared to AFP alone (0.756) with a sensitivity of 0.763 at a specificity of 0.80. 3-fold cross validation was further used to assess the performance of the optimal biomarker panel. Thus, a combination of fucosylated tetra-antennary glycoforms may serve as important markers for distinguishing HCC from cirrhosis.</pubmed_abstract><journal>Journal of proteome research</journal><pubmed_title>Integrative Analysis of Fucosylated Tetra Glycoforms in Hepatocellular Carcinoma: A NanoLC-PRM-MS/MS and Machine Learning Approach.</pubmed_title><pmcid>PMC12701774</pmcid><funding_grant_id>R01 CA160254</funding_grant_id><funding_grant_id>R01-CA160254-11</funding_grant_id><funding_grant_id>U01 CA283935</funding_grant_id><funding_grant_id>U01 CA271887</funding_grant_id><funding_grant_id>CA283935</funding_grant_id><pubmed_authors>Vadivalagan C</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Bass K</pubmed_authors><pubmed_authors>Singal AG</pubmed_authors><pubmed_authors>Parikh ND</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Dai J</pubmed_authors><pubmed_authors>Lubman DM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Integrative Analysis of Fucosylated Tetra Glycoforms in Hepatocellular Carcinoma: A NanoLC-PRM-MS/MS and Machine Learning Approach.</name><description>Hepatocellular carcinoma (HCC), commonly associated with cirrhosis, is a major cause of cancer-related mortality due to its poor prognosis. Herein, we investigated fucosylated glycoforms of serum haptoglobin (Hp) as potential biomarkers for HCC of metabolic associated dysfunction associated liver disease (MASLD) and alcohol related liver disease (ALD) etiologies. We analyzed 119 patient samples, including 60 with cirrhosis and 59 with HCC. Isolated Hp protein was digested using trypsin and Glu-C, and site-specific &lt;i>N&lt;/i>-glycans were quantified using PRM with LC-HCD-MS/MS. Differential analysis revealed significant variations in fucosylated tetra-antennary glycoforms at N241(VVLHPN&lt;sup>241&lt;/sup>YSQVD and VVLHPN&lt;sup>241&lt;/sup>YSQVDIGLIK), particularly in distinguishing cirrhosis and HCC (&lt;i>P&lt;/i> &lt; 0.05). A combined analysis of identified tetra-antennary fucosylated markers, along with AFP, gender, and age, demonstrated improved AUC. Tetra-antennary glycoforms exhibited an AUC of 0.871 (95% CI: 0.80-0.93) when incorporated into the AFP + age + gender + marker panel compared to AFP alone (0.756) with a sensitivity of 0.763 at a specificity of 0.80. 3-fold cross validation was further used to assess the performance of the optimal biomarker panel. Thus, a combination of fucosylated tetra-antennary glycoforms may serve as important markers for distinguishing HCC from cirrhosis.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T03:39:24.239Z</modification><creation>2026-05-25T03:07:47.298Z</creation></dates><accession>S-EPMC12701774</accession><cross_references><pubmed>41212027</pubmed><doi>10.1021/acs.jproteome.5c00626</doi></cross_references></HashMap>